Compare AbbVie Inc (ABBV) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

TLH trades at $97.05 with minimal daily movement (+0.23%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock maintains consistent dividend payments, with recent payouts of $0.41, $0.36, and $0.38 per share. Market sentiment reflects broader bond market concerns as Treasury yields rise amid inflation uncertainty and geopolitical tensions.

The outlook remains cautious with bearish technical indicators dominating and macroeconomic pressures from rising interest rates. Dividend stability provides some support, but the stock faces headwinds from bond market volatility and inflation concerns that could impact future performance.